

HR 4242

To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy.

Congress: 118 (2023–2025, Ended)

Chamber: House

Policy Area: Health

Introduced: Jun 21, 2023

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Jun 23, 2023)

Official Text: <https://www.congress.gov/bill/118th-congress/house-bill/4242>

Sponsor

Name: Rep. Crenshaw, Dan [R-TX-2]

Party: Republican • **State:** TX • **Chamber:** House

Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Khanna, Ro [D-CA-17]	D · CA		Jun 21, 2023
Rep. Miller-Meeks, Mariannette [R-IA-1]	R · IA		Jun 21, 2023

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Jun 23, 2023

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Jun 21, 2023)

This bill requires the Food and Drug Administration (FDA) to issue guidance on considerations for conducting clinical trials for psychedelic assisted therapy, including how to request support from the FDA for related investigational use exemptions.

Actions Timeline

- **Jun 23, 2023:** Referred to the Subcommittee on Health.
- **Jun 21, 2023:** Introduced in House
- **Jun 21, 2023:** Referred to the House Committee on Energy and Commerce.